| 000 | 01636 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515181018.0 | ||
| 264 | 0 | _c20101210 | |
| 008 | 201012s 0 0 eng d | ||
| 022 | _a1463-1326 | ||
| 024 | 7 |
_a10.1111/j.1463-1326.2009.01055.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCharpentier, G | |
| 245 | 0 | 0 |
_aEarlier triple therapy with pioglitazone in patients with type 2 diabetes. _h[electronic resource] |
| 260 |
_bDiabetes, obesity & metabolism _cSep 2009 |
||
| 300 |
_a844-54 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBlood Glucose _xanalysis |
| 650 | 0 | 4 |
_aC-Peptide _xblood |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlycated Hemoglobin _xmetabolism |
| 650 | 0 | 4 |
_aHomeostasis _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aInsulin _xblood |
| 650 | 0 | 4 |
_aInsulin Resistance _xphysiology |
| 650 | 0 | 4 |
_aLipids _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetformin _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPioglitazone |
| 650 | 0 | 4 |
_aProinsulin _xblood |
| 650 | 0 | 4 |
_aSulfonylurea Compounds _xtherapeutic use |
| 650 | 0 | 4 |
_aThiazolidinediones _xtherapeutic use |
| 700 | 1 | _aHalimi, S | |
| 773 | 0 |
_tDiabetes, obesity & metabolism _gvol. 11 _gno. 9 _gp. 844-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1463-1326.2009.01055.x _zAvailable from publisher's website |
| 999 |
_c19024177 _d19024177 |
||